Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04067089
Other study ID # TEAm-BR
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 10, 2018
Est. completion date December 31, 2023

Study information

Verified date March 2023
Source Hospital do Coracao
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TEAM-Br is a randomized, prospective, cost-utility study comparing transcatheter aortic valve implantation (TAVI) versus surgical aortic vale replacement in Brazil. The study is sponsored by the national Minister of Health, through PROADI-SUS (Programa de Apoio ao Desenvolvimento Institucional do SUS).


Description:

Transcatheter aortic valve implantation has been shown to be non-inferior to surgical aortic valve replacement in patients with severe aortic stenosis at high, intermediate and low surgical risk. In recent years, a concept of a simplified and optimized TAVR procedure (known as minimalist approach) has led experienced centers to perform the majority of these procedures using conscious sedation and local anesthesia only. From a clinical perspective, this approach is associated with better and faster recovery and mobilization, reduced need for a prolonged intensive care unit (ICU) stay and faster hospital discharge, as compared to general anesthesia. The cost-effectiveness of minimalist TAVR strategy - as compared to surgery - in Brazil is uncertain. Our objective is to conduct a cost-utility analysis comparing minimalist transcatheter aortic valve implantation with surgical aortic valve replacement in patients with severe aortic stenosis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 126
Est. completion date December 31, 2023
Est. primary completion date September 13, 2023
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Age > 70 years; - Symptoms of heart failure NYHA class > II; - Severe aortic stenosis (as defined by echocardiography: mean gradient >40 mmHg or jet velocity greater than 4.0 m/s or an initial aortic valve area of < 1.0 cm2) - Heart team (including examining cardiac surgeon) agree on eligibility including assessment that TAVR or SAVR is appropriate; - The study patient or the study patient's legal representative informed of the nature of the study, agreed to its provisions and provided written informed consent as approved by the Institutional Review Board (IRB) center; - The study patient agreed to comply with all required post-procedure follow-up visits including visits through 1 month and 1 year; - Heart team agreed (a priori) on treatment strategy for concomitant coronary disease (if present); - Patient agreed to undergo surgical aortic valve replacement (SAVR) if randomized to control treatment. Exclusion Criteria: - Heart Team assessment of inoperability (including examining cardiac surgeon); - Hostile chest - Evidence of an acute myocardial infarction = 1 month (30 days) before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB = twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)]; - Concomitant severe valvular disease (mitral, tricuspid or pulmonic) requiring surgical intervention; - Preexisting mechanical or bioprosthetic aortic valve with dysfunction; - Complex coronary artery disease: unprotected left main coronary artery, Syntax score > 32 (in the absence of prior revascularization); - Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not an exclusion criteria; - Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), thrombocytopenia (Plt < 50,000 cell/mL); - Hypertrophic cardiomyopathy with or without obstruction (HOCM); - Severe ventricular dysfunction with LVEF < 20%; - Echocardiographic evidence of intracardiac mass, thrombus or vegetation; - Active upper GI bleeding within 3 months (90 days) prior to procedure; - A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure; - Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 6 months (180 days) of the procedure; - Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy at the time of screening; - Estimated life expectancy < 24 months (730 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease; - Currently participating in an investigational drug or another device study; - Active bacterial endocarditis within 6 months (180 days) of procedure; - Patient refuses surgery for aortic valve replacement.

Study Design


Intervention

Procedure:
TAVR - Transcatheter aortic valve replacement
TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
Surgical aortic valve replacement
Surgical aortic valve replacement

Locations

Country Name City State
Brazil Hospital do Coracao Sao Paulo SP

Sponsors (1)

Lead Sponsor Collaborator
Hospital do Coracao

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cost-utility of minimalist TAVR as compared to SAVR Quality-adjusted life-years (QALYs). Quality of life will be assessed by EuroQol 5D. 1 year
Primary Cost-utility of minimalist TAVR as compared to SAVR Incremental cost-effectiveness ratio (ICER) 1 year
Secondary Clinical outcomes All-cause mortality, cardiovascular mortality, disabling stroke, acute renal failure, bleeding, major vascular complications, atrial fibrillation and permanent pacemaker implantation 30 days and 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Completed NCT01676727 - ADVANCE Direct Aortic Study
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A